IL146378A0 - Alpha v integrin receptor antagonists - Google Patents
Alpha v integrin receptor antagonistsInfo
- Publication number
- IL146378A0 IL146378A0 IL14637800A IL14637800A IL146378A0 IL 146378 A0 IL146378 A0 IL 146378A0 IL 14637800 A IL14637800 A IL 14637800A IL 14637800 A IL14637800 A IL 14637800A IL 146378 A0 IL146378 A0 IL 146378A0
- Authority
- IL
- Israel
- Prior art keywords
- receptor antagonists
- integrin receptor
- alpha
- present
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13710199P | 1999-06-02 | 1999-06-02 | |
| US17921600P | 2000-01-31 | 2000-01-31 | |
| PCT/US2000/014901 WO2000072801A2 (en) | 1999-06-02 | 2000-05-30 | Alpha v integrin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL146378A0 true IL146378A0 (en) | 2002-07-25 |
Family
ID=26834930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14637800A IL146378A0 (en) | 1999-06-02 | 2000-05-30 | Alpha v integrin receptor antagonists |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6410526B1 (de) |
| EP (1) | EP1187592B1 (de) |
| JP (3) | JP3808707B2 (de) |
| KR (1) | KR20020021380A (de) |
| CN (1) | CN1589145A (de) |
| AT (1) | ATE368462T1 (de) |
| AU (1) | AU749351B2 (de) |
| BG (1) | BG106232A (de) |
| BR (1) | BR0011108A (de) |
| CA (1) | CA2373937A1 (de) |
| CY (1) | CY1107746T1 (de) |
| CZ (1) | CZ20014308A3 (de) |
| DE (1) | DE60035779T2 (de) |
| DK (1) | DK1187592T3 (de) |
| DZ (1) | DZ3263A1 (de) |
| EA (1) | EA200101272A1 (de) |
| EE (1) | EE200100642A (de) |
| ES (1) | ES2288861T3 (de) |
| HR (1) | HRP20010895A2 (de) |
| HU (1) | HUP0302468A2 (de) |
| IL (1) | IL146378A0 (de) |
| IS (1) | IS6157A (de) |
| NO (1) | NO323906B1 (de) |
| PL (1) | PL353364A1 (de) |
| PT (1) | PT1187592E (de) |
| SK (1) | SK17442001A3 (de) |
| TR (1) | TR200103431T2 (de) |
| WO (1) | WO2000072801A2 (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| EP1254116A4 (de) | 2000-01-24 | 2003-04-23 | Merck & Co Inc | Alpha v integrin-rezeptor antagonisten |
| WO2001096334A2 (en) | 2000-06-15 | 2001-12-20 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
| AU2001277935B2 (en) * | 2000-07-26 | 2005-08-04 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| WO2002022616A2 (en) * | 2000-09-14 | 2002-03-21 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| US20050101593A1 (en) * | 2000-10-04 | 2005-05-12 | Meissner Robert S. | Phosphoric acid salt of an integrin receptor antagonist |
| EP1349548A4 (de) * | 2001-01-03 | 2004-06-02 | Merck & Co Inc | Verfahren und zusammensetzungen zur behandlung von parodontose |
| US20040136949A1 (en) | 2001-04-24 | 2004-07-15 | Matthias Grell | Combination therapy using anti-angiogenic agents and tnf alpha |
| JP2005533001A (ja) * | 2002-03-04 | 2005-11-04 | メディミューン，インコーポレーテッド | インテグリンαｖβ３アンタゴニストを他の物質と併用投与する癌の予防または治療方法 |
| EP1487489A4 (de) * | 2002-03-04 | 2008-10-01 | Medimmune Inc | VERFAHREN ZUR PRÄVENTION ODER BEHANDLUNG VON ERKRANKUNGEN DURCH VERABREICHUNG EINES INTEGRIN avb3 ANTAGONISTEN IN KOMBINATION MIT EINEM HMG-CoA REDUKTASE-HEMMER ODER EINEM BISPHOSPHONAT |
| US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| WO2004058760A1 (en) | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Thiazole compounds as integrin receptor antagonists derivatives |
| US7288655B2 (en) * | 2003-03-07 | 2007-10-30 | Merck & Co., Inc. | α v integrin receptor antagonists |
| US8604185B2 (en) | 2004-07-20 | 2013-12-10 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| EP2338518A1 (de) | 2006-01-18 | 2011-06-29 | Merck Patent GmbH | Spezifische Krebsbehandlung mit Integrin-Liganden |
| MX2009007597A (es) | 2007-01-18 | 2009-07-22 | Merck Patent Gmbh | Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer. |
| CL2008000467A1 (es) * | 2007-02-14 | 2008-08-22 | Janssen Pharmaceutica Nv | Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma |
| US9345739B2 (en) | 2007-11-08 | 2016-05-24 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
| BRPI1011206A2 (pt) | 2009-05-25 | 2016-03-15 | Merck Patent Gmbh | administração contínua de ligantes de integrina para tratar câncer |
| US8901144B2 (en) | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
| RS56711B1 (sr) * | 2013-02-07 | 2018-03-30 | Scifluor Life Sciences Inc | Fluorirani antagonisti integrina |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| PT3929196T (pt) | 2013-09-24 | 2023-09-11 | Fujifilm Corp | Composição farmacêutica de um novo composto contendo azoto ou seu sal, ou seu complexo de metal |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| EP3925959A1 (de) * | 2015-02-19 | 2021-12-22 | OcuTerra Therapeutics, Inc. | Fluorierte derivate von 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propansäure und verwendungen davon |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| US10118929B2 (en) | 2016-04-27 | 2018-11-06 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
| JP2019524702A (ja) * | 2016-07-05 | 2019-09-05 | ザ ロックフェラー ユニバーシティー | テトラヒドロナフチルリジンペンタンアミドインテグリンアンタゴニスト |
| EP3509590A4 (de) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | N-acyl-aminosäure-verbindungen und verfahren zur verwendung |
| KR102510858B1 (ko) * | 2016-11-08 | 2023-03-15 | 브리스톨-마이어스 스큅 컴퍼니 | 알파 v 인테그린 억제제로서의 아졸 아미드 및 아민 |
| WO2018089355A1 (en) * | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors |
| WO2018160522A1 (en) | 2017-02-28 | 2018-09-07 | Lazuli, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| CA3054604A1 (en) | 2017-02-28 | 2018-09-07 | Morphic Therapeutic, Inc. | Inhibitors of .alpha.v.beta.6 integrin |
| TW202035400A (zh) | 2018-08-29 | 2020-10-01 | 美商莫菲克醫療股份有限公司 | 抑制αvβ6整合素 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3843798A (en) | 1973-03-12 | 1974-10-22 | Stanley Drug Products Inc | Methods and compositions for inducing resistance to bacterial infections |
| US5025025A (en) | 1989-06-28 | 1991-06-18 | Ciba-Geigy Corporation | (Arylsulfonamido- and pyridyl-)-substituted carboxylic acids and derivatives thereof and use for suppressing thromboxane activity |
| HUT68769A (en) | 1991-05-07 | 1995-07-28 | Merck & Co Inc | FIBRINOGéN RECEPTOR ANTAGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS EFFECTIVE SUBSTANCE |
| AU3141693A (en) | 1991-11-22 | 1993-06-15 | Friedman, Mark M. | Non-peptidic surrogates of the arg-gly-asp sequence and pharmaceutical compositions comprising them |
| AU674553B2 (en) | 1992-10-14 | 1997-01-02 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| CA2190870A1 (en) | 1994-05-27 | 1995-12-07 | George D. Hartman | Compounds for inhibiting osteoclast-mediated bone resorption |
| EP0880511A4 (de) | 1996-01-16 | 1999-06-16 | Merck & Co Inc | Integrin-rezeptor-antagonisten |
| PT796855E (pt) | 1996-03-20 | 2002-07-31 | Hoechst Ag | Inibicao da reabsorcao nos ossos e antagonistas de vitronectina |
| JP2000508319A (ja) | 1996-04-10 | 2000-07-04 | メルク エンド カンパニー インコーポレーテッド | αｖβ３拮抗薬 |
| US5668159A (en) | 1996-05-08 | 1997-09-16 | The Dupont Merck Pharmaceutical Company | 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists |
| AU724191B2 (en) | 1996-08-29 | 2000-09-14 | Merck & Co., Inc. | Integrin antagonists |
| EP0946165B1 (de) * | 1996-10-30 | 2003-04-09 | Merck & Co., Inc. | Integrin antagonist |
| EP0946164A4 (de) | 1996-10-30 | 2000-08-23 | Merck & Co Inc | Integrin antagonisten |
| CA2277273C (en) | 1997-01-17 | 2008-03-25 | Merck & Co., Inc. | Integrin antagonists |
| US6017926A (en) | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| ATE299023T1 (de) | 1997-12-17 | 2005-07-15 | Merck & Co Inc | Integrinrezeptor antagonisten |
| IL136495A0 (en) * | 1997-12-17 | 2001-06-14 | Merck & Co Inc | Integrin receptor antagonists |
| EP1047425A4 (de) | 1997-12-17 | 2009-04-22 | Merck & Co Inc | Integrinrezeptor antagonisten |
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| ATE298338T1 (de) | 1997-12-17 | 2005-07-15 | Merck & Co Inc | Integrin-rezeptor-antagonisten |
-
2000
- 2000-05-30 ES ES00942652T patent/ES2288861T3/es not_active Expired - Lifetime
- 2000-05-30 DZ DZ003263A patent/DZ3263A1/fr active
- 2000-05-30 EA EA200101272A patent/EA200101272A1/ru unknown
- 2000-05-30 CA CA002373937A patent/CA2373937A1/en not_active Abandoned
- 2000-05-30 BR BR0011108-2A patent/BR0011108A/pt not_active IP Right Cessation
- 2000-05-30 CZ CZ20014308A patent/CZ20014308A3/cs unknown
- 2000-05-30 HU HU0302468A patent/HUP0302468A2/hu unknown
- 2000-05-30 AU AU57246/00A patent/AU749351B2/en not_active Ceased
- 2000-05-30 DE DE60035779T patent/DE60035779T2/de not_active Expired - Fee Related
- 2000-05-30 TR TR2001/03431T patent/TR200103431T2/xx unknown
- 2000-05-30 AT AT00942652T patent/ATE368462T1/de not_active IP Right Cessation
- 2000-05-30 IL IL14637800A patent/IL146378A0/xx unknown
- 2000-05-30 PT PT00942652T patent/PT1187592E/pt unknown
- 2000-05-30 EP EP00942652A patent/EP1187592B1/de not_active Expired - Lifetime
- 2000-05-30 PL PL00353364A patent/PL353364A1/xx not_active Application Discontinuation
- 2000-05-30 DK DK00942652T patent/DK1187592T3/da active
- 2000-05-30 SK SK1744-2001A patent/SK17442001A3/sk unknown
- 2000-05-30 EE EEP200100642A patent/EE200100642A/xx unknown
- 2000-05-30 KR KR1020017015498A patent/KR20020021380A/ko not_active Application Discontinuation
- 2000-05-30 JP JP2000620913A patent/JP3808707B2/ja not_active Expired - Fee Related
- 2000-05-30 CN CNA00811157XA patent/CN1589145A/zh active Pending
- 2000-05-30 WO PCT/US2000/014901 patent/WO2000072801A2/en active IP Right Grant
- 2000-05-31 US US09/583,522 patent/US6410526B1/en not_active Expired - Fee Related
-
2001
- 2001-11-13 IS IS6157A patent/IS6157A/is unknown
- 2001-11-30 HR HR20010895A patent/HRP20010895A2/xx not_active Application Discontinuation
- 2001-11-30 NO NO20015858A patent/NO323906B1/no not_active IP Right Cessation
- 2001-12-18 BG BG106232A patent/BG106232A/xx unknown
-
2006
- 2006-03-29 JP JP2006091926A patent/JP2006232844A/ja not_active Withdrawn
- 2006-03-29 JP JP2006091925A patent/JP2006206604A/ja not_active Withdrawn
-
2007
- 2007-09-27 CY CY20071101242T patent/CY1107746T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL146378A0 (en) | Alpha v integrin receptor antagonists | |
| DE69720771D1 (en) | Integrin antagonist | |
| PL341095A1 (en) | Compounds acting as antagonists of integrin receptor | |
| DE69829996D1 (de) | Integrin-rezeptor-antagonisten | |
| EP1044001A4 (de) | Integrinrezeptor antagonisten | |
| ES2185009T3 (es) | Antagonistas de alfa y beta 3'. | |
| AU7793501A (en) | Alpha v integrin receptor antagonists | |
| WO2002090325A3 (en) | Benzazepinone alpha v integrin receptor antagonists | |
| AU3943502A (en) | Dibenzoxazepine alpha v integrin receptor antagonist | |
| YU38200A (sh) | Antagonisti integrinskog receptora | |
| YU38300A (sh) | Antagonisti integrinskog receptora |